ALS News Today Home | ALS News Today
Nov 20, 2024 · Brain scans may predict ALS risk in C9ORF72 mutation carriers. People with mutations in the C9ORF72 gene who develop amyotrophic lateral sclerosis (ALS) show signs of damage to certain brain regions years before the appearance of disease symptoms, a …
News Archives - ALS News Today
Brain scans may predict ALS risk in C9ORF72 mutation carriers. People with mutations in the C9ORF72 gene who develop amyotrophic lateral sclerosis (ALS) show signs of damage to certain brain regions years before the appearance of disease symptoms, a study reports.
FDA final approval decision on NurOwn for ALS due by year’s end
Jun 8, 2023 · Subsequent analysis excluding patients with more severe ALS showed evidence of the therapy’s effectiveness in slowing ALS progression, with statistically significant differences in ALSFR-R.
Phase 1 clinical trial of experimental ALS therapy ... - ALS News …
Aug 28, 2023 · Combining AKV9 with the approved ALS therapies riluzole (sold as Rilutek, among others) and edaravone (sold as Radicava and Radicava ORS) led to even greater improvements in upper motor neuron health in additional experiments in a similar mouse model.
Results of Phase 3 Trial of TUDCA in Slowing ALS ... - ALS News …
Nov 25, 2022 · Findings from the TUDCA-ALS trial in 337 adults, testing oral TUDCA plus riluzole in slowing ALS progression, are likely in late 2023.
S-oxprenolol granted orphan drug status by FDA as ALS treatment
Sep 6, 2024 · The FDA has granted orphan drug status to Actimed Therapeutics' S-oxprenolol, a treatment candidate that aims to ease muscle wasting in ALS.
New B-cell therapy eases disease severity, delays onset: Study
Jul 19, 2024 · A new B-cell therapy safely eased disease severity and extended survival in ALS mice, and a human patient also saw benefits, per a study.
ALS Study Results Clear Way to Test Utreloxastat on Patients | ALS …
Jan 30, 2023 · Utreloxastat, an investigational therapy for ALS, was safe and displayed promising pharmacological properties in study of healthy people.
MDA 2024: Planned Phase 3b trial aims to support ... - ALS News …
Mar 6, 2024 · Planned yearlong trial to enroll 200 people with mild-to-moderate ALS. This yearlong, two-part study is expected to recruit about 200 adults, ages 18 to 75, with mild-to-moderate disease and ALS symptom onset less than two years before enrolling.
Kadimastem, NLS merge to advance ALS therapy AstroRx, other …
Nov 13, 2024 · The cell-based therapy significantly reduced disease progression, as assessed by the decline on ALS Functional Rating Scale Revised scores, by 53% over the first three months. The effect was greater in patients who received the higher dose and in those with rapidly progressing disease.